Literature DB >> 27652977

Predictive value of DCE-MRI for early evaluation of pathological complete response to neoadjuvant chemotherapy in resectable primary breast cancer: A single-center prospective study.

Ying-Shi Sun1, Ying-Jian He2, Jie Li3, Yan-Ling Li3, Xiao-Ting Li3, Ai-Ping Lu4, Zhao-Qing Fan2, Kun Cao3, Tao Ouyang5.   

Abstract

OBJECTIVE: This study proposed to establish a predictive model using dynamic enhanced MRI multi-parameters for early predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer.
METHODS: In this prospective cohort study, 170 breast cancer patients treated with NAC were enrolled and were randomly grouped into training sample (136 patients) and validation sample (34 patients). DCE-MRI parameters achieved at the end of the first cycle of NAC were screened to establish the predictive model by using multivariate logistic regression model according to pCR status. Receiver operating characteristic curves were conducted to assess the predictive capability. The association between MRI-predicted pCR and actual pCR in survival outcomes was estimated by using the Kaplan-Meier method with log-rank test.
RESULTS: Multivariate analysis showed ΔAreamax and ΔSlopemax were independent predictors for pCR, odds ratio were 0.939 (95%CI, 0.915 to 0.964), and 0.966 (95%CI, 0.947 to 0.986), respectively. A predictive model was established using training sample as "Y = -0.063*ΔAreamax - 0.034*ΔSlopemax", a cut-off point of 3.0 was determined. The AUC for training and validation sample were 0.931 (95%CI, 0.890-0.971) and 0.971 (95%CI, 0.923-1.000), respectively. MRI-predicted pCR patients showed similar RFS (p = 0.347), DDFS (p = 0.25) and OS (p = 0.423) with pCR patients.
CONCLUSION: The multi-parameter MRI model can be potentially used for early prediction of pCR status at the end of the first NAC cycle, which might allow timely regimen refinement before definitive surgical treatment.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Magnetic resonance imaging; Pathological complete response; Prediction; Therapeutic response

Mesh:

Substances:

Year:  2016        PMID: 27652977     DOI: 10.1016/j.breast.2016.08.017

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

Review 1.  MRI Performance in Detecting pCR After Neoadjuvant Chemotherapy by Molecular Subtype of Breast Cancer.

Authors:  Nancy Yu; Vivian W Y Leung; Sarkis Meterissian
Journal:  World J Surg       Date:  2019-09       Impact factor: 3.352

2.  Breast MRI radiomics for the pretreatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients.

Authors:  Karen Drukker; Alexandra Edwards; Christopher Doyle; John Papaioannou; Kirti Kulkarni; Maryellen L Giger
Journal:  J Med Imaging (Bellingham)       Date:  2019-09-30

3.  Host genetic modifiers of nonproductive angiogenesis inhibit breast cancer.

Authors:  Michael J Flister; Shirng-Wern Tsaih; Alexander Stoddard; Cody Plasterer; Jaidip Jagtap; Abdul K Parchur; Gayatri Sharma; Anthony R Prisco; Angela Lemke; Dana Murphy; Mona Al-Gizawiy; Michael Straza; Sophia Ran; Aron M Geurts; Melinda R Dwinell; Andrew S Greene; Carmen Bergom; Peter S LaViolette; Amit Joshi
Journal:  Breast Cancer Res Treat       Date:  2017-05-31       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.